Repairing function, not only managing symptoms
Regenerative medicine combines cell and developmental biology, immunology, genomics, biomaterials, tissue engineering and clinical science. Strategies may stimulate the body’s own repair programmes or deliver biologically active cells, cell-derived products, engineered tissues or instructive materials.1
The central goal is biological recovery. Depending on the indication, that may mean restoring vascular supply, reshaping inflammation, limiting fibrosis, replacing a missing cell population or creating an environment in which tissue can repair itself.
A broad therapeutic toolkit
The field includes living cells, extracellular vesicles, organoids, scaffolds, hydrogels, extracellular matrices, growth factors and gene-modified cells. Each has a distinct mechanism, manufacturing pathway and risk profile; they should not be treated as interchangeable.2
- Activate endogenous repair pathways
- Support angiogenesis and microvascular remodelling
- Modulate immune and fibrotic responses
- Replace or reconstruct cells and tissues
Evidence before implementation
Regenerative medicine is not one treatment. A technology that is promising in a laboratory model is not automatically safe or effective for patients. Clinical use requires indication-specific evidence, reproducible manufacturing and appropriate regulatory oversight.3
Measurement
How regeneration is demonstrated
A regenerative claim should be supported by converging evidence: tissue structure, molecular and cellular state, organ function, symptoms and durable clinical outcomes. A laboratory biomarker or imaging change alone does not establish that a tissue has recovered its function.1
Longitudinal studies are especially important because early anti-inflammatory effects may not persist. Interpretation should include baseline disease severity, concomitant treatment, a comparator group and prespecified clinically meaningful endpoints.